DR. JOSEPH LASKY, MD
Osteopathic Medicine at Tulane Ave, New Orleans, LA
License number
Louisiana 09692R
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
1415 Tulane Ave, New Orleans, LA 70112
Phone
(504) 988-2300
(504) 988-8886 (Fax)
(504) 988-8886 (Fax)
Personal information
See more information about JOSEPH LASKY at radaris.comName
Address
Phone
472 Walnut St, New Orleans, LA 70118
1415 Tulane Ave, New Orleans, LA 70112
472 Walnut St, New Orleans, LA 70118
839 Arabella St, New Orleans, LA 70115
Organization information
See more information about JOSEPH LASKY at bizstanding.comJoseph Lasky MD
1415 Tulane Ave, New Orleans, LA 70112
Industry:
Internist
Phone:
(504) 988-2177 (Phone)
Joseph Alexander Lasky
Professional information
See more information about JOSEPH LASKY at trustoria.com
Joseph A Lasky, New Orleans LA
Joseph A Lasky, New Orleans LA
Specialties:
Pulmonologist
Address:
1415 Tulane Ave, New Orleans, LA 70112
Education:
University of Minnesota, Medical School - Doctor of Medicine
The Mayo Clinic - Fellowship - Pulmonary Disease (Internal Medicine)
The Mayo Clinic - Residency - Internal Medicine
The Mayo Clinic - Fellowship - Pulmonary Disease (Internal Medicine)
The Mayo Clinic - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Use Of N-'5-'4-(4-Methylpiperaziomethyl)-Benzoylamido!-2-Methylphenyl!-4-(3-Pyridyl)2-Pyridine-Amine For The Treatment Of Pulmonary Hypertension
Use Of N-'5-'4-(4-Methylpiperaziomethyl)-Benzoylamido!-2-Methylphenyl!-4-(3-Pyridyl)2-Pyridine-Amine For The Treatment Of Pulmonary Hypertension
US Patent:
2006015, Jul 13, 2006
Filed:
Oct 20, 2003
Appl. No.:
10/532297
Inventors:
Joseph Lasky - New Orleans LA, US
International Classification:
A61K 31/506
US Classification:
514252180
Abstract:
The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I
or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.
Use Of N--4-(3-Pyridyl)-2-Pyridine-Amine For The Treatment Of Pulmonary Hypertension
Use Of N--4-(3-Pyridyl)-2-Pyridine-Amine For The Treatment Of Pulmonary Hypertension
US Patent:
2012021, Aug 23, 2012
Filed:
Apr 30, 2012
Appl. No.:
13/459896
Inventors:
Joseph Alexander Lasky - New Orleans LA, US
International Classification:
A61K 31/506, A61P 9/12
US Classification:
51425218
Abstract:
The compound of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula Ior a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.
Use Of N--4-(3-Pyridyl)-2-Pyridine-Amine For The Treatment Of Pulmonary Hypertension
Use Of N--4-(3-Pyridyl)-2-Pyridine-Amine For The Treatment Of Pulmonary Hypertension
US Patent:
2011004, Feb 24, 2011
Filed:
Nov 3, 2010
Appl. No.:
12/938846
Inventors:
Joseph Alexander LASKY - New Orleans LA, US
International Classification:
A61K 31/506, A61P 11/00, A61P 9/12
US Classification:
51425218
Abstract:
The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula Ior a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.
Co-Administration Of Arsenic Compounds And Anti-Herpes Virus Anti-Virals
Co-Administration Of Arsenic Compounds And Anti-Herpes Virus Anti-Virals
US Patent:
2014001, Jan 16, 2014
Filed:
Apr 6, 2012
Appl. No.:
14/007142
Inventors:
Mark D. Sides - New Orleans LA, US
Joseph A. Lasky - New Orleans LA, US
Joseph A. Lasky - New Orleans LA, US
Assignee:
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND - New Orleans LA
International Classification:
A61K 33/36, A61K 45/06, A61K 31/522
US Classification:
424623
Abstract:
It has now been discovered that arsenic induces herpes viruses latent in infected cells to reactivate to the lytic stage. Herpes viruses in the lytic stage activate anti-herpes virus anti viral agents. Co-administration of arsenic compounds and anti-herpes viral agents to a population of cells infected with a herpes virus results in the death of the cells and inhibits proliferation of the virus. The invention is therefore useful for reducing a subject's population of cells infected with herpes viruses, particularly Epstein-Barr virus.
4-(4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide For Treating Pulmonary Fibrosis
4-(4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide For Treating Pulmonary Fibrosis
US Patent:
2007008, Apr 12, 2007
Filed:
Jun 17, 2003
Appl. No.:
10/518988
Inventors:
Joseph Lasky - New Orleans LA, US
International Classification:
A61K 31/506
US Classification:
514252180
Abstract:
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I
or a pharmaceutically acceptable salt thereof can be used in the treatment of pulmonary fibrosis.